Evogene (NASDAQ:EVGN – Get Free Report) is expected to post its quarterly earnings results before the market opens on Thursday, March 6th. Analysts expect Evogene to post earnings of ($0.73) per share and revenue of $3.63 million for the quarter. Individual that wish to listen to the company’s earnings conference call can do so using this link.
Evogene Stock Performance
Shares of EVGN stock opened at $1.33 on Wednesday. The stock’s fifty day moving average is $1.59 and its two-hundred day moving average is $2.09. The firm has a market capitalization of $7.14 million, a P/E ratio of -0.30 and a beta of 1.29. Evogene has a fifty-two week low of $1.20 and a fifty-two week high of $10.00.
Wall Street Analysts Forecast Growth
Separately, StockNews.com initiated coverage on Evogene in a report on Sunday. They issued a “sell” rating on the stock.
About Evogene
Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.
Featured Stories
- Five stocks we like better than Evogene
- How to Short a Stock in 5 Easy Steps
- GitLab: Get In While It’s Down—Big Rebound Ahead
- Find and Profitably Trade Stocks at 52-Week Lows
- Tesla Stock: Finding a Bottom May Take Time
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- Duolingo: This Beaten-Down Stock Is About to Rally 38%
Receive News & Ratings for Evogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evogene and related companies with MarketBeat.com's FREE daily email newsletter.
